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The Eﬀect of Orally Administered Ranitidine and Once-Daily or Twice-
Daily Orally Administered Omeprazole on Intragastric pH in Cats
S. Sutalo, M. Ruetten, S. Hartnack, C.E. Reusch, and P. H. Kook
Background: Gastric acid suppressants frequently are used in cats with acid-related gastric disorders. However, it is not
known if these drugs eﬀectively increase intragastric pH in cats.
Objectives: To examine the eﬀects of PO administered ranitidine and omeprazole on intragastric pH in cats and to com-
pare the eﬃcacy of once-daily versus twice-daily dosage regimens for omeprazole.
Animals: Eight domestic shorthair cats.
Methods: Using a randomized 4-way cross-over design, cats were given enteric-coated omeprazole granules (1.1–1.3 mg/
kg q24h and q12h), ranitidine (1.5–2.3 mg/kg q12h), and placebo. Intragastric pH was monitored continuously for 96 hours
using the BravoTM systema, starting on day 4 of treatment, followed by a median washout period of 12 days. Mean percent-
age of time pH was ≥3 and ≥4 was compared among groups using repeated measures ANOVA.
Results: Mean  SD percentage of time intragastric pH was ≥3 and ≥4 was 67.0  24.0% and 54.6  26.4% for twice-
daily omeprazole, 24.4  22.8% and 16.8  19.3% for once-daily omeprazole, 16.5  9.0% and 9.6  5.9% for ranitidine,
and 9.4  8.0% and 7.0  6.6% for placebo administration. Twice-daily omeprazole treatment signiﬁcantly increased intraga-
stric pH, whereas pH after once-daily omeprazole and ranitidine treatments did not diﬀer from that of placebo-treated cats.
Conclusion and Clinical Importance: Only twice-daily PO administered omeprazole signiﬁcantly suppressed gastric acidity in
healthy cats, whereas once-daily omeprazole and standard dosages of ranitidine were not eﬀective acid suppressants in cats.
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Acid-related gastric disorders result from an imbal-ance between gastric acid secretion and gastric acid
mucosal defense mechanisms.1 In humans, gastric
acidity plays an important role in gastric ulcer develop-
ment, and numerous studies have been conducted on the
eﬃcacy of PO administration of acid-suppressing drugs.2
In veterinary medicine, the role of gastric acidity in the
pathogenesis of gastric erosive and ulcerative disease has
received limited attention, and the most appropriate extent
of gastric acid inhibition for acid-related diseases has yet
to be determined in small animals.3 Although gastric ero-
sive disease is commonly suspected in cats, especially in
critically ill and stressed cats, it is diﬃcult to conﬁrm
because of the inherent invasiveness of gastric mucosal
visual inspection. Instead, gastric acid suppressants includ-
ing histamine-2 receptor antagonists, such as ranitidine or
famotidine, and proton pump inhibitors, such as omepra-
zole, are widely used empirically in this species.
Although some information on the antisecretory
eﬀects of commonly used acid suppressants (e.g. omep-
razole, famotidine, ranitidine) is available for dogs,4–6
the clinical eﬃcacy of antisecretory drugs in cats is lar-
gely unknown. The Existing data on feline gastric pH,
derived from studies that used the cat as a model for
humans, are diﬃcult to interpret because gastric acid
secretion was pharmacologically modiﬁed or experi-
ments were carried out in anesthetised cats that had
been vagotomized, and pH measurements were deter-
mined for only a few hours.7–10 Despite the relative
paucity of studies in cats, acid suppressant medications
are commonly used in clinical practice, using dosages
extrapolated from studies performed in dogs.4,5
The recent introduction of pH monitoring devices such
as the BravoTM systema has allowed noninvasive, continu-
ous assessment of intragastric pH over prolonged peri-
ods. This technique has been evaluated for extended
recordings of intragastric pH in dogs.4,11 The eﬀects of
twice-daily omeprazole versus standard dosages of famo-
tidine on intragastric pH in cats recently have been
reported using this new technique. The Results of this
study indicated that omeprazole administration provided
superior acid suppression compared with famotidine.12
The goals of the present study were to determine nor-
mal gastric acid proﬁles in healthy cats, to investigate
the eﬀect of omeprazole and ranitidine on intragastric
pH in a placebo-controlled study and to compare once-
daily and twice-daily dosage regimens for omeprazole.
We hypothesized that omeprazole would be superior
to ranitidine for achieving a sustained increase in gastric
pH and that omeprazole administered twice daily would
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provide superior gastric acid control compared with a
once-daily dosage regimen.
Materials and Methods
Cats
Eight healthy European shorthair cats (2 intact females, 3
spayed females, 3 intact males), aged 5–6 years (median, 5.7 years)
and weighing 4.3–6.8 kg (median, 5.3 kg) with median body condi-
tion score of 5/9, were used. All cats were research colony cats
from the Institute of Animal Nutrition of our institution. The cats
had no clinical signs of gastrointestinal disease for the past
6 months and were deemed healthy based on physical examination
ﬁndings as well as the results of CBC, serum biochemistry proﬁle
and urinalysis. The study was approved by the Cantonal Veteri-
nary Oﬃce of Z€urich and conducted in accordance with the guide-
lines established by the Animal Welfare Act of Switzerland
(permission no. 527/2013). Permission for the use of animals in
our study speciﬁed that cats with anorexia, vomiting persisting
>24 hours, weight loss exceeding 10% of body weight, or some
combination of those would be excluded. During intragastric pH
recording periods, pairs of cats were housed in
140 9 105 9 100 cm cages and had daily physical exercise.
Study Design
Using a randomized cross-over design, cats received 1 of the
following treatments PO for 7 consecutive days: placebo (empty
gelatin capsule)b q12h, ranitidinec (1.5–2.3 mg/kg; median,
1.9 mg/kg) q12 h, omeprazoled (1.1–1.3 mg/kg; median, 1.2 mg/
kg) q24h, or omeprazoled (1.1–1.3 mg/kg; median, 1.2 mg/kg)
q12 h. The goal of treatment was to achieve a dosage of approxi-
mately 1 mg/kg for omeprazole, thus, 1 enteric-coated granule
containing 1.1 mg omeprazole was given per kg body weight (e.g.
a 10 mg omeprazole capsuled contained 9 enteric-coated granules
each consisting of 1.1-mg omeprazole).e The dosage of each drug
was consistent among treatments for each cat. All drugs were
administered in hard gelatin capsules.b To facilitate swallowing,
approximately 1 teaspoon of a highly palatable feline foodf was
fed immediately after administration of the capsule. Cats were
medicated daily at 6:30 am and 6:30 pm, 30 minutes before a
standardized morning and evening meal.g The once-daily omepra-
zole treatment was given in the morning. One of the authors (SS)
stayed with the cats for a minimum of 45 minutes after treatment
to ensure that medication was not regurgitated or vomited. Each
treatment period was followed by a median washout period of 12
days (range, 7–24 days). Attitude, appetite, body weight, number
of defecations, and fecal consistency were recorded daily. Feces
were graded from 1 to 7 (1, very hard; 7, watery) according to a
standardized fecal scoring system.h
On day 4 of each treatment period, cats were anesthetized after
a 12-hour fast for endoscopy-assisted placement of a pH capsule.a
Cats were premedicated with butorphanoli (0.2 mg/kg IM) and
medetomidinej (5 lg/kg IM), an IV catheter was placed, and gen-
eral anesthesia was induced with propofol and maintained with
isoﬂurane. Before the ﬁrst pH capsule placement, routine gastric
and duodenal endoscopic biopsy was performed. The biopsy sam-
ples were ﬁxed in 10% buﬀered formalin, embedded in paraﬃn,
cut into 2-lm sections and stained using a routine protocol with
hematoxylin and eosin. Gastrointestinal biopsy specimens were
assessed by a board-certiﬁed pathologist (MR) according to World
Small Animal Veterinary Association guidelines.13 All pH capsules
were placed under direct endoscopic guidance by the same investi-
gator (PHK). Immediately before placement, the capsules were
calibrated with commercial buﬀer solutions (pH 1.07 and 7.01)
according to the manufacturer’s instructions.a A drift of 0.1 pH
units was tolerated. All pH capsules were anchored in the fundic
area using the supplied delivery system that combined suction and
a lock-and-pin mechanism.
The approach for gastric capsule placement was similar to
what has been described recently in dogs,4,11 with the exception
that the external vacuum suction (510 mm Hg) applied to the
capsule delivery system was decreased from approximately 30 sec-
onds to a median of 20 seconds during the study.k After capsule
placement, gastric pH recordings were obtained telemetrically at
6-second sampling intervals for 4 days (96 hours). The receiver
was kept in close proximity outside of the feline’s cage. After
acquisition, pH data were uploaded from the receiver to the com-
puter using the manufacturer software.l Percentage of time intra-
gastric pH was ≥3 and ≥4 and in 1 of each of 8 categories (pH
0–1, pH 1–2, up to pH 7–8) was calculated by the computer soft-
ware. Throughout the study, all cats were subjected to visual
inspection 4 times daily and were allowed to play in a separate
enclosure twice daily. A chaperone (SS) was present during these
times to entertain the cats and to ensure that the distance to the
receiver was adequate.
Investigation of Capsule Dissolution
Because all medications were administered in hard gelatin cap-
sulesb, an experiment was conducted to examine the drug release
time at diﬀerent pH levels. Dissolution of gelatin capsules contain-
ing enteric-coated omeprazole granulesd and ranitidinec was
examined visually in transparent cups containing 35 ml of phos-
phate-buﬀered saline (PBS) buﬀer solution that was warmed to
body temperature (37.5 C) and had a pH of 1, 2, 3, 4, 5, 6, or 7.
Statistical Analyses
Commercially available softwarem was used for analysis.
Repeated measures ANOVA was used to analyze diﬀerences
among the 4 treatment arms regarding (1) percentage of time in-
tragastric pH was ≥3 and ≥4 during the 96-hour period after pH
capsule placement (days 4–7 of treatment), (2) percentage of time
intragastric pH was in 1 of 8 pH categories (0–1, 1–2, 2–3, 3–4, 4–
5, 5–6, 6–7, 7–8) for days 4–7 of treatment; and (3) adverse eﬀects
of treatments by comparing the 7-day mean number of defecations
with fecal scores ≥3 and ≥4.
In a second analysis, the diﬀerent treatment arms were assessed
separately and the eﬀect of day was evaluated with repeated mea-
sures ANOVA. Assumption of sphericity was examined by Mau-
chly’s test of sphericity and a Bonferroni correction was applied to
multiple comparisons. Diﬀerences were considered signiﬁcant at
P < 0.05.
Results
Cats
All cats were alert and active and had a normal appe-
tite throughout the study. A single episode of vomiting
occurred 2 days after BravoTM capsule placement in 1 of
the cats in the twice-daily omeprazole treatment arm.
Assessment of Fecal Scores
The occurrence of fecal scores >3 and >4 did not dif-
fer among treatment arms. The median fecal score was
3 for the placebo, 4 for ranitidine, 4 for once-daily
treatment with omeprazole, and 4 for twice-daily
administration of omeprazole.
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Experience with the BravoTM Systema in Cats
Overall, 32 BravoTM capsules were successfully
attached to the fundic mucosa. Total procedure times
for endoscopy-assisted capsule placement ranged from 5
to 8 minutes, with most procedures taking <5 minutes.
In 1 cat, the stomach still contained food, and mucosal
capsule attachment was unsuccessful because food rem-
nants obstructed the suction hole. Capsule placement
and pH measurement were repeated at a later time
point. In 4 cases, the previously attached capsule was
still in place at the time of the subsequent pH measure-
ment (Fig. 1). Because endoscopic removal of the cap-
sule with the help of endoscopic foreign body retrieval
devices and polypectomy forceps was unsuccessful in
the ﬁrst case, a new capsule was attached next to the
other 1 in these 4 cats. No problems were encountered
with this approach. Passing of pH capsules through the
digestive tract was veriﬁed by daily fecal examination in
all cats. A total of 2,909 hours and 20 minutes of intra-
gastric pH recording time (equivalent to 1,745,580 pH
readings) was obtained. The maximum possible data
acquisition was 3,072 hours (96 hours per cat per treat-
ment). Therefore, the overall missing data rate was
5.3%. Missing data were caused by signal interference
in the radiotelemetric system, which occurred intermit-
tently in all treatment groups.
Endoscopic and Histologic Assessment of
Gastrointestinal Biopsy Samples
Gastroduodenoscopic evaluation was normal in all
cats. Histologic examination of endoscopic gastric biopsy
samples showed severe colonization of the mucosal
surface with spiral-shaped organisms interpreted as gas-
tric Helicobacter spp. in all of the cats. There were no
concurrent lesions in the mucosa or lamina propria. The
villi of the intestine were slender and had normal archi-
tecture with a crypt-to-villi ratio of 1:4. The epithelium
was normal but in the lamina propria, small clusters of
9–12 neutrophils per high power ﬁeld (hpf) were
observed in 5 cats. The remaining 3 cats had smaller clus-
ters of 4–5 neutrophils per hpf scattered in the lamina
propria. The ﬁnal histologic diagnosis was gastric coloni-
zation by Helicobacter spp. Duodenal tissue was deemed
normal.
Assessment of Capsule Dissolution
The capsules started to swell within 2 minutes of
being placed in the PBS buﬀer solution. Complete disin-
tegration of the capsules and release of the contents
occurred within 5 minutes at all pH levels.
Intragastric pH Recordings
With respect to percentage of time intragastric pH
was ≥3 and ≥4, twice-daily omeprazole had a signiﬁ-
cantly greater eﬀect than once-daily omeprazole, raniti-
dine, and placebo administration. There were no
signiﬁcant diﬀerences among the latter 3 treatment
arms.
Mean  SD percentage of time intragastric pH was
≥3 and ≥4 was 67.0  24.0% and 54.6  26.4% for
twice-daily omeprazole administration, 24.4  22.8%
and 16.8  19.3% for once-daily omeprazole adminis-
tration, 16.5  9.0% and 9.6  5.9% for ranitidine
administration, and 9.4  8.0 and 7.0  6.6% for pla-
cebo administration (Fig. 2).
The treatment arms diﬀered with respect to the distri-
bution of intragastric pH over pH categories 1–8
(Fig. 3). For pH category 1–2, twice-daily omeprazole
administration diﬀered signiﬁcantly from the other
treatment arms (placebo, P = 0.02; once-daily omepra-
zole, P = 0.024; ranitidine, P = 0.040). For categories
3–4, 4–5, 5–6, and 6–7, twice-daily omeprazole diﬀered
signiﬁcantly from placebo, and for pH categories 4–5,
5–6, and 6–7, ranitidine diﬀered signiﬁcantly from pla-
cebo. To summarize, intragastric pH ranged widely
across all pH categories with all treatments; but twice-
daily omeprazole resulted in the largest amount of time
intragastric pH was in categories 3–4 to 6–7.
Comparison of treatment days within a given treat-
ment identiﬁed a signiﬁcant increase in intragastric pH
between days 4 and 7 only for twice-daily omeprazole
(P = 0.011 for pH ≥3; P = 0.044 for pH ≥4).
Discussion
Although more commonly encountered in dogs, gas-
tric erosive and ulcerative disease can exacerbate a
range of gastrointestinal, metabolic, or neoplastic condi-
tions14 or be a complication of nonsteroidal anti-inﬂam-
matory drug administration in cats.15 Gastric acid
suppressants currently are the treatment of choice for
Fig. 1 View of the BravoTM capsule attached to the feline gastric
mucosa. Compared to dogs,11 comparatively large parts of the gas-
tric mucosa became lodged in the suction well of the capsule.
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these conditions. Because information on the eﬃcacy of
antisecretory drugs is scarce in cats,9,b the goal of the
present study was to compare the eﬀects of PO adminis-
tered gastric acid suppressants commonly used in cats.
Our study clearly demonstrated that twice-daily omep-
razole administration provided superior gastric acid
suppression compared with a once-daily dosage regimen
and with standard dosages of ranitidine and placebo
based on percentage of time intragastric pH was ≥3 and
≥4. The conceptual basis for these cut-oﬀs has been
explored by meta-analysis of many trials in human
medicine, and these cut-oﬀs are now considered ideal
for promoting optimal gastrointestinal ulcer healing.16,17
Comparison of once-daily and twice-daily omeprazole
administration was chosen because additional drug
administration could pose a substantial problem for
sick cats and would likely result in poor owner compli-
ance. A twice-daily dosage regimen used in small ani-
mals has been largely extrapolated from studies of
humans.18 A simpliﬁed omeprazole suspension (enteric-
coated granules suspended in 8.4% sodium bicarbonate)
administered to dogs as a bolus through a stomach tube
resulted in superior gastric acid suppression over
24 hours compared with once-daily omeprazole.5
Another study in dogs found that the eﬀect of once-
daily administration of reformulated omeprazole paste
used in horses for gastric acid secretion waned substan-
tially during 24 hours after administration.4 It therefore
was postulated that a twice-daily dosage regimen was
more beneﬁcial. It was surprising that the once-daily
dosage of omeprazole in the present study had poor
results in cats because comparable omeprazole dosages
in dogs yielded a mean percentage of time with intraga-
stric pH ≥3 of 70.2% and ≥4 of 52.3%.5 Species-speciﬁc
diﬀerences such as increased de novo biosynthesis of
proton pumps may account for this diﬀerence because
restoration of acid secretion is dependent on pump bio-
synthesis.18 Delayed gastric release of omeprazole from
the gelatin capsule with inadequate intestinal absorption
caused by variability in the hardness of the capsule
walln was ruled out as a cause of the unexpected low in-
tragastric pH because the capsules were shown to dis-
solve quickly at all pH levels.
The eﬀects of ranitidine and placebo on intragastric pH
did not diﬀer in the present study, which is in contrast to
a recent report that PO administered famotidine in cats
had better antisecretory eﬃcacy than placebo.b Ranitidine
and famotidine were shown to have poor antisecretory
properties in dogs.4,5 We anticipated similar results, based
on observations that plasma gastrin concentrations did
not increase in cats undergoing long-term ranitidine treat-
ment.9 This indicates that ranitidine has weak antisecreto-
ry properties because gastrin release is inhibited by the
presence of acid in the stomach by a negative feedback
mechanism. Nevertheless, we felt it was important to pro-
vide substantial evidence that ranitidine also is a weak
acid suppressant in cats and therefore should not be used
for treatment of acid-related gastric disorders in cats.
We used enteric-coated omeprazole granules rather
than splitting tablets because a dosage of 1 mg/kg can
be more easily approximated by administering 1 granule
per kg body weight (1 granule contains 1.1 mg omepra-
zole),d which is convenient in small patients. Omepra-
zole granules are also used in human pediatric patients
and when medication must be given through a feeding
tube.19–21 Moreover, it was felt that splitting enteric-
coated omeprazole tablets may adversely aﬀect drug
eﬃcacy. However, results published during the course
Fig. 2 Comparison of eﬃcacy of various treatments on intragastric pH. Box plots show variation in percentage of time intragastric pH
was ≥3 (blue) and ≥4 (green) for 8 cats given placebo, ranitidine, once-daily omeprazole and twice-daily omeprazole. *Results were signiﬁ-
cantly increased compared with placebo, ranitidine, and once-daily omeprazole (P = 0.011 for pH ≥3; P = 0.044 for pH ≥4).
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of the present investigation showed that fractionated
enteric-coated omeprazole tablets remained eﬀective
acid suppressants in cats despite disruption of the
enteric coating.12
To facilitate swallowing of the capsule, a teaspoon of
highly palatable canned feline foodf was fed immedi-
ately after pill administration. Administration of water
by syringe usually is recommended after oral drug
administration in cats.22 However, the cats in our study
did not tolerate syringe feeding of water, but readily ate
the small amount of foodf. This procedure is likely
more practical for owners who administer drugs to their
cats at home, and we do not believe that the small
amount of food compromised the eﬃcacy of the medi-
cation. The administration of omeprazole granules to
children in an acidic or alkaline solution or mixed with
apple sauce resulted in acid suppression comparable
with that of intact capsules in humans.19,23 Similarly, a
study of omeprazole absorption in humans indicated
that the area under the curve of omeprazole was simi-
lar, and that the total amount of drug absorbed was
not aﬀected when the granules were given immediately
before or after breakfast.24
We chose the BravoTM pH monitoring systema
because we found it reliable and minimally invasive for
extended continuous gastric pH monitoring in dogs.11
This system allows longer measurement periods than
catheter-based pH probes.5 Compared with dogs, a
shorter vacuum application time (approximately 20 sec-
onds) worked better for pH capsule placement in cats.
In the 4 cats with pH capsules still in place at the time
of second capsule application, the vacuum was applied
for ≥25 seconds, and we believe a larger part of the gas-
tric mucosa became lodged in the suction well of the
capsule (Fig. 1) compared with what we observed in
dogs.11 Inclusion of the lamina muscularis may have
added to the rigidity of the attachment. Attempts to
remove the ﬁrst capsule failed, and we left them in
place. We were aware of a case of gastric perforation
related to endoscopic removal of a BravoTM capsule,25,a
and it is possible that our attempts at removal were too
conservative.
Soft feces has been associated with PO administered
omeprazole treatment in humans and dogs,4,5,26 but
how suppression of gastric acid secretion predisposes
patients to this adverse eﬀect is not well understood.
A C
B D
Fig. 3 Box plots representing the intragastric pH distribution for 8 cats receiving placebo (A), ranitidine (B), once-daily omeprazole (C),
and twice-daily omeprazole (D). Circles represent outliers.
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We used fecal score cut-oﬀs of 3 and 4 and found that
the treatments did not diﬀer with respect to feces con-
sistency.
Histologic examination of gastric and duodenal
biopsy samples was done to rule out occult gastrointes-
tinal disease that could have interfered with parietal cell
function or duodenal drug absorption. In all cats, the
gastric mucosa was heavily colonized with Helicobacter
spp., but no evidence of gastritis was observed. In
humans, the relationship between gastritis caused by
H. pylori and gastric acid secretion is controversial, and
normal acid secretion as well as hyper- and hypo-chlor-
hydria have been reported.1 Although the severity of
gastritis did not seem to be correlated with gastric acid
secretion, omeprazole treatment resulted in higher gas-
tric pH in human patients infected with H. pylori than
in patients free of H. pylori.27 This eﬀect of omeprazole
is believed to be present because of the neutralization of
substances produced by H. pylori.27 We believe this sce-
nario to be unlikely in the cats of our study because
H. pylori infection is extremely rare in cats28 and evi-
dence of gastritis was not detected in the present study.
Given the overall high prevalence of gastric mucosal
colonization with Helicobacter spp. without concurrent
gastritis in cats,28 we concluded that gastric histology
results were typical of what is seen in cats. The princi-
pal goal of histologic examination was to rule out
occult gastric disease, which could have aﬀected gastric
acid secretion, and small bowel disease,29 which could
have aﬀected drug absorption. The relationship between
gastric acid secretion and Helicobacter spp. colonization
in cats requires further study.
A signiﬁcant increase in intragastric pH between days
4 and 7 was only recorded after twice-daily omeprazole
administration, which was similar to reports in humans
in which multiple omeprazole doses were needed for
optimal eﬀect.23,30 True drug eﬃcacy might be greater
after multiple doses than what we were able to docu-
ment during the 96-hour study period. Considering the
strong and long-lasting attachment of the capsule to the
gastric mucosa in cats when using a vacuum time
>25 seconds, it should be possible to study the eﬃcacy
of gastric acid suppressants for longer than 4 days.
We saw considerable individual variation in response
to treatment with omeprazole and much less so with
ranitidine. For example, 1 cat consistently had close to
100% acid suppression (e.g. percentage of time pH was
≥4 was 95% when treated with twice-daily omeprazole),
whereas another had extremely poor acid suppression
(percentage of time pH was ≥4 was 3% when treated
with twice-daily omeprazole). These ﬁndings are similar
to those observed in humans23,31 and may be a conse-
quence of genetic polymorphism in the hepatic cyto-
chrome P-450 system involved in the metabolism of
omeprazole, which is a well-established explanation for
people who do not respond to gastric acid suppres-
sants.32 In fact, recent studies on the acid suppressant
eﬀects of proton pump inhibitors in humans include
analysis of cytochrome 450 genes and report pH mea-
surements based on results of genotyping (i.e. extensive,
intermediate, and poor metabolizers).33
The washout periods used in the present study varied
slightly among treatments subject to staﬀ availability.
However, we feel that the protocols used in our experi-
ments precluded drug carryover eﬀects. The minimum
washout period of 7 days (n = 5) pertained to 3 exam-
inations preceded by placebo and 2 preceded by raniti-
dine. The next shortest washout period was 9 days
(n = 2), pertaining to 2 examinations preceded by once-
daily omeprazole. A minimum of 1 week washout per-
iod was chosen because full restoration of gastric acid
secretion was shown 7 days after long-term administra-
tion of ranitidine in cats9 and 5 days after long-term
administration of omeprazole in people.34
In conclusion, twice-daily administration of omepra-
zole granules appears to be the treatment of choice for
cats with acid-related gastrointestinal disease. Raniti-
dine and once-daily omeprazole cannot be recom-
mended as acid suppressants in cats.
Footnotes
a BravoTM pH monitoring system, Given Imaging, Yoqneam,
Israel.
b Gelatin capsules size 5, Interdelta SA, 1762 Givisiez, Switzer-
land.
c Ranitidin 20 mg, Christoﬀel-Apotheke, Christoﬀelgasse 3, 3001
Bern, Switzerland.
d Omezol-Mepha MT 10, Mepha Pharma AG, 4010 Basel, Swit-
zerland.
e email communication with Ms. Linda K€otter-Spirgi (07.24.2014),
Mepha Pharma AG, 4010 Basel, Switzerland.
f Hill’s Prescription Diet Canine/Feline a/d.
g Hill’s Science Diet Optimal Care Original Adult Cat Food.
h Faecal Scoring System, Nestle Purina PetCare Company, St
Louis, MO, USA.
i Morphasol, Graeub AG, Rehhagstrasse 83, 3018 Bern, Switzer-
land
j Dorbene, Graeub AG, Rehhagstrasse 83, 3018 Bern, Switzerland.
k email communication with Dr. Katie Tolbert (21.10.2013)
l Polygram Net Software, Given Imaging, Yoqneam, Israel.
m SPSS, version 11, SPSS Inc, Chicago, IL, USA.
n https://www.edqm.eu/en/european-pharmacopoeia-8th-edition-
1563.html
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